Thus, our work involves the participation of PML to p53 regulation in ccRCC providing a previously unknown avenue to exploit p53 reactivation, one that can be pharmacologically explored with an FDA-approved leukemia treatment that promotes PML degradation: arsenic trioxide. Here, TP53 is linked to nonpapillary renal cell carcinoma.